314 related articles for article (PubMed ID: 31601682)
1. Therapeutic Effects of Nrf2 Activation by Bardoxolone Methyl in Chronic Heart Failure.
Tian C; Gao L; Zhang A; Hackfort BT; Zucker IH
J Pharmacol Exp Ther; 2019 Dec; 371(3):642-651. PubMed ID: 31601682
[TBL] [Abstract][Full Text] [Related]
2. The Methyl Ester of 2-Cyano-3,12-Dioxooleana-1,9-Dien-28-Oic Acid Reduces Endometrial Lesions Development by Modulating the NFkB and Nrf2 Pathways.
Siracusa R; D'Amico R; Cordaro M; Peritore AF; Genovese T; Gugliandolo E; Crupi R; Impellizzeri D; Cuzzocrea S; Fusco R; Di Paola R
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33924360
[TBL] [Abstract][Full Text] [Related]
3. The NRF2 activator DH404 attenuates adverse ventricular remodeling post-myocardial infarction by modifying redox signalling.
Bubb KJ; Kok C; Tang O; Rasko NB; Birgisdottir AB; Hansen T; Ritchie R; Bhindi R; Reisman SA; Meyer C; Ward K; Karimi Galougahi K; Figtree GA
Free Radic Biol Med; 2017 Jul; 108():585-594. PubMed ID: 28438659
[TBL] [Abstract][Full Text] [Related]
4. CDDO-Im exerts antidepressant-like effects via the Nrf2/ARE pathway in a rat model of post-stroke depression.
Hou X; Liu H; Ping Y; Zhang F; Zhi L; Jiang X; Zhang F; Song C; Zhang Z; Song J
Brain Res Bull; 2021 Aug; 173():74-81. PubMed ID: 33991607
[TBL] [Abstract][Full Text] [Related]
5. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease.
Aminzadeh MA; Reisman SA; Vaziri ND; Khazaeli M; Yuan J; Meyer CJ
Xenobiotica; 2014 Jun; 44(6):570-8. PubMed ID: 24195589
[TBL] [Abstract][Full Text] [Related]
6. Myocardial infarction-induced microRNA-enriched exosomes contribute to cardiac Nrf2 dysregulation in chronic heart failure.
Tian C; Gao L; Zimmerman MC; Zucker IH
Am J Physiol Heart Circ Physiol; 2018 May; 314(5):H928-H939. PubMed ID: 29373037
[TBL] [Abstract][Full Text] [Related]
7. CDDO-Me Inhibits Microglial Activation and Monocyte Infiltration by Abrogating NFκB- and p38 MAPK-Mediated Signaling Pathways Following Status Epilepticus.
Kim JE; Park H; Lee JE; Kang TC
Cells; 2020 May; 9(5):. PubMed ID: 32370011
[TBL] [Abstract][Full Text] [Related]
8. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease.
Aminzadeh MA; Reisman SA; Vaziri ND; Shelkovnikov S; Farzaneh SH; Khazaeli M; Meyer CJ
Redox Biol; 2013; 1(1):527-31. PubMed ID: 24363993
[TBL] [Abstract][Full Text] [Related]
9. Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties.
Wang YY; Yang YX; Zhe H; He ZX; Zhou SF
Drug Des Devel Ther; 2014; 8():2075-88. PubMed ID: 25364233
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils.
Thimmulappa RK; Fuchs RJ; Malhotra D; Scollick C; Traore K; Bream JH; Trush MA; Liby KT; Sporn MB; Kensler TW; Biswal S
Antioxid Redox Signal; 2007 Nov; 9(11):1963-70. PubMed ID: 17822364
[TBL] [Abstract][Full Text] [Related]
11. A Point Mutation at C151 of
Gatbonton-Schwager T; Yagishita Y; Joshi T; Wakabayashi N; Srinivasan H; Suzuki T; Yamamoto M; Kensler TW
Mol Pharmacol; 2023 Aug; 104(2):51-61. PubMed ID: 37188495
[TBL] [Abstract][Full Text] [Related]
12. The effect of ex vivo CDDO-Me activation on nuclear factor erythroid 2-related factor 2 pathway in white blood cells from patients with septic shock.
Noel S; Zheng L; Navas-Acien A; Fuchs RJ
Shock; 2014 Nov; 42(5):392-9. PubMed ID: 25105464
[TBL] [Abstract][Full Text] [Related]
13. Identification and quantification of the basal and inducible Nrf2-dependent proteomes in mouse liver: biochemical, pharmacological and toxicological implications.
Walsh J; Jenkins RE; Wong M; Olayanju A; Powell H; Copple I; O'Neill PM; Goldring CE; Kitteringham NR; Park BK
J Proteomics; 2014 Aug; 108(100):171-87. PubMed ID: 24859727
[TBL] [Abstract][Full Text] [Related]
14. CDDO-Me Attenuates Vasogenic Edema and Astroglial Death by Regulating NF-κB p65 Phosphorylations and Nrf2 Expression Following Status Epilepticus.
Kim MJ; Park H; Choi SH; Kong MJ; Kim JE; Kang TC
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31574956
[TBL] [Abstract][Full Text] [Related]
15. Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice.
Sussan TE; Rangasamy T; Blake DJ; Malhotra D; El-Haddad H; Bedja D; Yates MS; Kombairaju P; Yamamoto M; Liby KT; Sporn MB; Gabrielson KL; Champion HC; Tuder RM; Kensler TW; Biswal S
Proc Natl Acad Sci U S A; 2009 Jan; 106(1):250-5. PubMed ID: 19104057
[TBL] [Abstract][Full Text] [Related]
16. Bardoxolone methyl modulates efflux transporter and detoxifying enzyme expression in cisplatin-induced kidney cell injury.
Atilano-Roque A; Aleksunes LM; Joy MS
Toxicol Lett; 2016 Sep; 259():52-59. PubMed ID: 27480280
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Anticancer Activity of CDDO and CDDO-Me, Two Derivatives of Natural Triterpenoids.
Borella R; Forti L; Gibellini L; De Gaetano A; De Biasi S; Nasi M; Cossarizza A; Pinti M
Molecules; 2019 Nov; 24(22):. PubMed ID: 31766211
[TBL] [Abstract][Full Text] [Related]
18. Butein Inhibits Oxidative Stress Injury in Rats with Chronic Heart Failure via ERK/Nrf2 Signaling.
Liu P; Pan Q
Cardiovasc Ther; 2022; 2022():8684014. PubMed ID: 35069800
[TBL] [Abstract][Full Text] [Related]
19. CDDO-Me, Sulforaphane and tBHQ attenuate the RANKL-induced osteoclast differentiation via activating the NRF2-mediated antioxidant response.
Xue P; Hu X; Powers J; Nay N; Chang E; Kwon J; Wong SW; Han L; Wu TH; Lee DJ; Tseng H; Ko CC
Biochem Biophys Res Commun; 2019 Apr; 511(3):637-643. PubMed ID: 30826055
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity.
Aleksunes LM; Goedken MJ; Rockwell CE; Thomale J; Manautou JE; Klaassen CD
J Pharmacol Exp Ther; 2010 Oct; 335(1):2-12. PubMed ID: 20605904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
